Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study.
OBJECTIVE
Chemotherapy-induced nausea and vomiting (CINV) is a side effect related to administration of the adjuvant temozolomide (TMZ) in patients affected by glioblastoma. After chemoradiotherapy, adjuvant TMZ is administered as an oral multiple-day regimen, and TMZ-associated CINV may interfere with the continuation of chemotherapy, with potentially negative consequences on clinical efficacy. The aim of the present study was to investigate the efficacy of palonosetron for prevention of CINV-induced by adjuvant TMZ.


METHODS
From March 2007 to August 2008, 33 patients with confirmed glioblastoma and eligible for adjuvant treatment with TMZ were enrolled in the study. All patients with responding or stable disease after concomitant radiotherapy plus daily TMZ (75 mg/m(2)) received a single i.v. bolus 0.25 mg of palonosetron 30 min before the beginning of adjuvant TMZ (150-200 mg/m(2)/day for five consecutive days every 4 weeks). The primary endpoint was the percentage of patients with complete response (CR), defined as no emetic episodes and no rescue medication during the overall phase (0-168 h). Secondary endpoints included CR during the 0-120 h and 0-168 h phases and complete control (CC; CR and no more than mild nausea) during the 0-120 h, 120-168 h, and 0-168 h phases.


RESULTS
Thirty-three patients were enrolled in the study (median age 57.6 years, 23 male and 10 female, median Karnofsky Performance Status = 80). Each patient was receiving fixed doses of dexamethasone (range 2-8 mg/day). CR in the 0-120 h, 120-168 h, and 0-168 h phases was seen in 91% of patients. CC was observed in 88%, 91%, and 88% of cases during the 0-120 h, 120-168 h, and 0-168 h phases, respectively. Anti-emetic prophylaxis with palonosetron was well tolerated and the most frequent adverse event was grade 1-2 headache reported by seven patients (21%).


CONCLUSIONS
A single dose of palonosetron before the initiation of multiple oral doses of TMZ, in patients on treatment with steady doses of dexamethasone, provides a high protection against CINV throughout the overall phase (0-168 h). The pharmacological profile of palonosetron, compared to first-generation 5-HT3 receptor antagonists, may have an impact on its clinical efficacy.
Rozzi
Antonio
A
Clinical Oncology Unit, Istituto Neurotraumatologico Italiano, Grottaferrata, Rome, Italy. antoniorozzi@virgilio.it
Nardoni
Chiara
C
Corona
Michela
M
Restuccia
Maria Rosa
MR
Fabi
Alessandra
A
Bria
Emilio
E
Minniti
Giuseppe
G
Lanzetta
Gaetano
G
D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000009:adverse effects / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects / Q000379:methods; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy / Q000532:radiotherapy; D006801:Humans; D007546:Isoquinolines / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D000077924:Palonosetron; D011812:Quinuclidines / Q000009:adverse effects / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000077204:Temozolomide; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D000932:Antiemetics; D018906:Antineoplastic Agents, Alkylating; D007546:Isoquinolines; D011812:Quinuclidines; D012702:Serotonin Antagonists; D000077924:Palonosetron; D003606:Dacarbazine; D003907:Dexamethasone; D000077204:Temozolomide
Future Oncol. 2006 Oct;2(5):591-602
17026451
Ann Oncol. 2006 Jun;17(6):952-6
16565212
Support Care Cancer. 2007 Nov;15(11):1293-1300
17436025
J Clin Oncol. 1997 Jan;15(1):103-9
8996130
Support Care Cancer. 2009 Feb;17(2):205-9
18839220
Ann Oncol. 1993 Jun;4(6):475-9
8353089
Ann Oncol. 2006 Dec;17(12):1835-41
16980601
Cancer J. 2006 Sep-Oct;12(5):341-7
17034670
Cancer. 2003 Dec 1;98(11):2473-82
14635083
Drugs. 1998 Feb;55(2):173-89
9506240
Nat Clin Pract Oncol. 2008 Jan;5(1):32-43
18097455
N Engl J Med. 2005 Mar 10;352(10):987-96
15758009
Ann Oncol. 2001 Feb;12(2):249-54
11300333
Br J Pharmacol. 1995 Feb;114(4):851-9
7773546
Ann Oncol. 2006 Sep;17(9):1441-9
16766588
Ann Oncol. 2003 Oct;14(10):1570-7
14504060
Anesth Analg. 2008 Aug;107(2):469-78
18633025
Support Care Cancer. 2005 Feb;13(2):112-6
15480812
J Natl Compr Canc Netw. 2007 Jan;5(1):51-9
17239326
Support Care Cancer. 2005 Feb;13(2):80-4
15599601
Drugs. 1996;52 Suppl 5:1-12
8922553
Ann Oncol. 2006 Jan;17(1):20-8
16314401